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Background: For those who initiate chronic dialysis, knowing what proportion will experience 3-year outcomes of
hemorrhage with hospitalization informs patient prognosis, disease impact, and the planning of trials and programs
to prevent events.
Objectives: We examined the incidence of hemorrhage and related gastrointestinal endoscopic procedures in
incident older dialysis patients and stratified patients by age, era, dialysis modality and whether recently prescribed
anti-thrombotic medication.
Design: Retrospective cohort study
Setting: Ontario, Canada from 1998 to 2008 (n = 11,173)
Patients: All older patients (>65 years) who initiated chronic dialysis
Measurements: Hospitalization with hemorrhage and its subtypes (upper and lower gastrointestinal, intra-cerebral,
subarachnoid) and related-gastrointestinal procedures.
Methods: Three-year outcomes of hospitalization with hemorrhage were expressed as cumulative incidence and
incidence rate (number of events per 1,000 patient years). Results were stratified by patient age (66 to 74, 75 to
84, ≥ 85), era (1998 to 2001, 2002 to 2005, 2006 to 2008) and dialysis modality. Among those with hemorrhage,
we examined prescriptions for anti-thrombotic medications (warfarin, clopidogrel) in the preceding 120 days.
Results: The 3-year cumulative incidence of hemorrhage was 14.4% (roughly 1 in 7 patients). By location, the 3-year
cumulative incidence was 8.9% lower gastrointestinal, 6.1% upper gastrointestinal, 0.9% intra-cerebral and 0.1% sub
arachnoid hemorrhage. The 3-year cumulative incidence of gastrointestinal endoscopic procedures was 14.8%. The
cumulative incidence and rate of hemorrhage were not appreciably different across the 3 age strata, by era or by
dialysis modality. Among patients with a hemorrhage, 29.5% were prescribed warfarin in the preceding 120 days,
and 8.4% clopidogrel.
Limitations: Recurrent events were not included.
Conclusions: Many older patients who initiate chronic dialysis will be hospitalized with hemorrhage and receive
related procedures over the subsequent three years. Despite greater age and co-morbidity over the last decade this
incidence has not changed.* Correspondence: msood99@gmail.com
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Contexte: Dans les cas de dialyse chronique, connaître la proportion de patients qui souffriront d’hémorragies
nécessitant une hospitalisation dans les trois années suivantes fournit un éclaircissement sur le pronostic des patients,
les répercussions de la maladie et la planification des essais et des programmes visant à prévenir ces épisodes.
Objectifs: Nous avons examiné l’incidence des hémorragies et des procédures gastro-intestinales endoscopiques
connexes chez les patients âgés débutant la dialyse, et les avons stratifiés par âge, par période, par modalité de
dialyse et selon qu’on leur a récemment prescrit des médicaments antithrombotiques.
Type d’étude: Étude rétrospective de cohorte
Contexte: Ontario, Canada, entre 1998 et 2008 (n = 11 173)
Participants: Tous les patients âgés (>65 ans) qui ont entamé une dialyse chronique
Mesures: L’hospitalisation avec hémorragie et sous-types (hémorragie digestive haute ou basse, intracérébrale,
sous-arachnoïdienne), de même que les procédures gastro-intestinales connexes.
Méthodes: Les cas d’hémorragies nécessitant l’hospitalisation dans les trois années suivantes sont exprimés en taux
d’incidence cumulatif et en taux d’incidence (nombre de cas pour 1 000 patients par année). Les résultats ont été
stratifiés par âge du patient (66 à 74, 75 à 84, ≥ 85), par période (1998 à 2001, 2002 à 2005, 2006 à 2008) et par
modalités de dialyse. Parmi ceux qui ont souffert d’hémorragie, nous avons examiné les prescriptions de médicaments
antithrombotiques (warfarine, clopidogrel) au cours des 120 jours précédents.
Résultats: Le taux d’incidence cumulatif des hémorragies sur trois ans était de 14,4% (environ 1 patient sur 7). Par
localisation du saignement, le taux d’incidence cumulatif sur trois ans indiquait une hémorragie digestive basse à 8,9%,
intracérébrale à 0,9% et sous-arachnoïdienne à 0,1%. Le taux d’incidence cumulatif des procédures gastro-intestinales
endoscopiques était de 14,8%. Le taux d’incidence cumulatif et le taux d’incidence des hémorragies ne variaient pas
sensiblement en fonction de l’âge, de la période ou de la modalité de dialyse. Parmi les patients ayant souffert
d’hémorragie, 29,5% ont reçu une prescription de warfarine au cours des 120 jours précédents, et 8,4%, de clopidorel.
Limites de l’étude: Les cas récurrents n’ont pas été considérés.
Conclusion: Plusieurs patients âgés qui entament une dialyse chronique seront hospitalisés pour hémorragie et
subiront les procédures connexes au cours des trois années suivantes. Malgré un âge plus avancé et une comorbidité
au cours de la dernière décennie, la fréquence n’a pas changé.What was known before
Dialysis patients are known to experience a significant
risk of hemorrhagic events. Accurate determination of the
risk has been difficult due to variations in the definition
of hemorrhage and the use of non-validated diagnostic
codes in previous studies. Further it remains unclear if
or to what magnitude the hemorrhagic risk changes
with increasing age and over time.
What this adds
We found that one in seven patients (14.43%) will ex-
perience a hospitalization with a hemorrhage within the
first three years of initiating dialysis and this high risk
did not increase with age or improve over time.
Background
Patients who initiate chronic dialysis are older, have more
co-morbid illness than a decade prior, and subsequently
may experience more hospitalizations in follow-up. Hem-
orrhages are one of most common hospital admission
diagnoses in the end-stage renal disease population
and contribute significant morbidity and mortality [1].Compared to the general population, the incidence of
hemorrhage is considerably higher in those receiving
dialysis with rates ranging from 35.4 to 80 per 1000-
patient years (which is contingent on the study design,
the definition used, method of outcome ascertainment
and concurrent use of anti-thrombotic medications
such as clopidogrel or warfarin) [2,3].
In the non-dialysis population, the incidence of he-
morrhagic events has been declining over the last two
decades, attributed to the widespread use of gastrointestinal
endoscopic procedures, treatments for H.pylori-related
ulcers and the use of proton pump inhibitors [4-8]. In
an American dialysis population, the incidence of non-
variceal upper gastrointestinal bleeding had not changed
over the last decade despite increasing patient comorbidity
[9,10]. It is unknown whether the same is true in other
jurisdictions, or applies to other types of bleeding (lower
gastrointestinal, intracranial bleeding) or related procedures
(gastrointestinal endoscopy). Furthermore, the risk of
bleeding appears to increase with advancing age [7]. In
the non-CKD, non-dialysis population, hospitalizations
for UGI hemorrhage per 100, 000 population increased
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with a similar trend observed for lower GI hemorrhage. As
the average age of incident dialysis patients is increasing
over time, it follows that there may a parallel rise in the
risk of major hemorrhage [11]. Lastly, the hemorrhagic
risk may differ based on the dialysis modality as patients
on peritoneal and hemodialysis are well known to differ
based on co-morbidities, exposures (to heparin with the
hemodialysis procedure) and functional status.
In this study we examined older adults who initiated
chronic dialysis in Ontario, Canada over a ten-year
period to determine the 3-year cumulative incidence and
incidence rate (per 1000 person years) of hemorrhage
and related gastrointestinal endoscopic procedures. We
further examined hemorrhage incidence across three
age (66 to 74, 75 to 84, ≥85), era (1998 to 2001, 2002 to
2005, 2006 to 2008) and dialysis modality (peritoneal,
hemodialysis) and considered whether patients with hemor-
rhagic events were recently prescribed anti-thrombotic
medication.
Methods
Study design and setting
We conducted a population-based study of all older adults
who initiated chronic dialysis in Ontario, Canada between
January 1, 1998 and December 31, 2008 using linked
health care databases. Ontario has approximately 13
million residents, 14% of whom are 65 years of age or
older [12]. Residents have universal access to hospital
care and physician services and those 65 years of age or
older have universal prescription drug coverage. All
healthcare encounters are entered in administrative
databases and are held in a linked, de-identified form at
the Institute for Clinical Evaluative Sciences (ICES). We
conducted this study according to a pre-specified protocol
that was approved by the research ethics board at Sunny-
brook Health Sciences Centre (Toronto, Canada). The
reporting of this study followed guidelines for observa-
tional studies [13] (Additional file 1: Table S1). Regional
ethics approval was obtained.
Data sources
We ascertained patient characteristics, drug use, covari-
ate information, and outcome data using records from
five linked databases. We identified patients initiating
chronic dialysis in Ontario through the Canadian Organ
Replacement Registry (CORR) [11]. CORR is a national
dialysis registry with information collected from all dialysis
facilities in Canada on incident chronic dialysis patients
[14,15]. The recorded information includes dialysis modal-
ity and the type of vascular access. We obtained vital
statistics from the Ontario Registered Persons Database
which contains demographic information on all Ontario
residents who have ever been issued a health card. Weused the Ontario Drug Benefit Plan database to identify
prescription drug use. This database contains highly
accurate records of all outpatient prescriptions dispensed
to patients aged 65 or older, with an error rate of less
than 1% [16]. We identified diagnostic and procedural
information on all hospitalizations from the Canadian
Institute for Health Information Discharge Abstract
Database (CIHI-DAD). We obtained information from the
Ontario Health Insurance Plan database, which includes
health claims for inpatient and outpatient physician
services. Previously, we have used these databases to
research renal health outcomes and health services
[17-19]. Whenever possible, we defined patient character-
istics, dialysis characteristics and outcomes using database
codes that have been proven reliable when compared with
manual chart review (Additional file 1: Table S2).
Patients
We studied patients who initiated chronic dialysis therapy
within our 10 year accrual period. CORR captures patients
who require chronic dialysis therapy; their date of dialysis
initiation served as the index date (also referred to as the
cohort entry date). We excluded the following people
from analysis: i) those without at least one year of eligibil-
ity for prescription drug coverage (age less than 66) to
avoid incomplete medication records, ii) those with a prior
history of kidney transplantation or prior chronic dialysis,
to focus on incident end-stage renal disease treated with
chronic dialysis and iii) those who initiated chronic dialysis
during a hospital stay and died prior to hospital discharge.
Known demographics and co-morbid risk factors for
hemorrhage were recorded including age, hypertension,
prior major hemorrhage [20], diabetes, cardiovascular
disease including prior myocardial infarction, and atrial
fibrillation in the five years preceding dialysis initiation.
Antithrombotic therapy (warfarin, clopidogrel) was cap-
tured in the 30 and 120 days preceding the hemorrhagic
event. In Ontario, acetyl-salicylic acid (ASA) is often
available without a prescription and thus would not be
captured in the Ontario Drug Benefit Plan.
Outcomes
All individuals were followed for three years after the
initiation of chronic dialysis for the outcomes of interest.
The primary outcome was the first hospitalization with
non-traumatic major hemorrhage, a composite outcome
defined by any of the following: upper and lower gastro-
intestinal (GI) hemorrhage, intra-cerebral hemorrhage
(ICH) and subarachnoid hemorrhage (SAH). The second-
ary outcome was each specific subtype of hemorrhage and
all gastrointestinal endoscopic procedures that occurred
during the hospital stay.
The components of non-traumatic major hemorrhage
were specifically selected based on prior validation studies
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have reported positive predictive values of 90-98% for
each of the specific subtypes of hemorrhage we used as
secondary outcomes [21,22]. Non-validated hemorrhages,
such as those associated with vascular access, and non-
severe hemorrhages (e.g. epistaxis) were excluded. Gastro-
intestinal endoscopic procedures included gastroscopy,
colonoscopy, sigmoidoscopy, duodenoscopy, & esophago-
scopy. Hospitalizations for outcomes were identified using
the International Classification for Disease (ICD), 9 and
10 codes (Additional file 1: Table S3).
Statistical analysis
The study period was categorized into three eras:
1998–2001, 2002–2005, 2006–2008, three age groups:
66–74, 75–84 and ≥85 years of age and dialysis modal-
ity (peritoneal dialysis and hemodialysis). Differences
between baseline characteristics were evaluated using
analysis of variance (ANOVA) and chi-squared tests.
We determined frequencies and calculated a modified
Charlson comorbidity index for all patients at baseline
by era [23].
We calculated the three-year cumulative incidence of
hemorrhagic events (defined as the proportion of patients
who experienced the event at least once within the
three-years of follow-up in percent) and three-year inci-
dence rates (defined as the rate per 1,000 person-years
of follow-up). For the primary outcome, patients were
censored at the time of their first hemorrhagic event, death
or end of follow-up period whereas for the secondary
outcome of subtypes of hemorrhage or related-procedures,
patients were censored only after the specific subtype of
hemorrhage or related-procedure occurred, death or the
end of the follow-up period. This allowed us to determine
the specific subtype or related procedure incidence. Primary
results were stratified by era (1998 to 2001, 2002 to 2005,
and 2006 to 2008), age category (65–74, 75–84, ≥85)
and dialysis modality. Trends were examined using the
Cochrane-Armitage test. We examined whether patients
with hemorrhage were prescribed anti-thrombotic medi-
cations (warfarin, clopidogrel) in the 30 days and 120 days
preceding their hemorrhagic event. Of note, the three-
year cumulative incidence does not account for time at
risk, representing simply a proportion of events achieved
with 3 years. In this regard, the incidence rate was also
calculated.
Results
Our final study cohort included 11, 173 incident chronic
dialysis patients comprising 19,894.2 patient-years of
follow-up with the average follow-up per person of
677 days (see cohort development Additional file 1: Figure
S1). Baseline characteristics by era and age are presented
in Table 1. Most patients were Caucasian (versus otherraces) and initiated hemodialysis (>80% of the cohort,
versus peritoneal dialysis). A history of atrial fibrillation
and hemorrhage were common in the older age groups.
Patients who initiated dialysis in more recent years
(versus earlier years) were slightly older and had greater
comorbidity. Prescriptions at dialysis initiation for warfarin
were unchanged (mean 12.2%, p = 0.098) whereas clopido-
grel significantly increased from 0.5 to 8.0% (p < 0.001)
in the more recent era compared to earlier. Among co-
morbidities prior to dialysis initiation, hemorrhage, acute
coronary syndrome and the presence of a mechanical
heart valve were more common in the recent era.
Three-year cumulative incidence and event rate of
hemorrhage
The three-year cumulative incidence of hemorrhage was
14.43% with an event rate of 52.64 per 1000 person years
(see Table 2). By site of bleeding, the cumulative incidence
and event rates were highest for lower gastrointestinal
(8.88% and 31.21 per 1000 person years) followed by
upper gastrointestinal (6.06% and 20.94 per 1000 person
years), intra-cerebral (0.85% and 2.85 per 1000 person
years) and subarachnoid (0.10% and 0.33 per 1000 person
years). The three-year cumulative incidence and event rate
for the receipt of gastrointestinal endoscopy (upper, lower)
was 14.86% and 54.45 per 1000 person years of patients.
Patients with hemorrhage at more than one anatomical
location occurred in 162 cases (1.45%).
Age and the three-year cumulative incidence and event
rate of hemorrhage
The 3-year cumulative incidence and event rate for hemor-
rhage was similar across age groups (see Figure 1). They
were highest in those 75–84 years of age (14.55%, 53.23 per
1000 person years) and lowest in those ≥ 85 years of age
(13.95%, 50.78 per 1000 person years). Individuals ≥ 85 years
of age had the highest 3-year cumulative incidence of lower
gastrointestinal hemorrhage (9.30%, 32.85 per 1000 person
years) and lowest incidence of upper gastrointestinal
hemorrhage (5.04%, 17.3 per 1000 person years) and
intra-cerebral hemorrhage (0.58%, 1.94 per 1000 person
years). Individuals’ ≥ 85 years of age underwent substan-
tially fewer gastrointestinal endoscopic procedures (9.59%,
34.14 per 1000 person years, p = 0.005) than those in the
other 2 age categories.
Secular trends in the rates of hemorrhage
The 3-year cumulative incidence rates and event rates
(per 1000 person years) of hemorrhage were consistent
across time periods and varied from 14.15 to 14.36% and
51.57 to 52.29 (see Table 3). The highest 3-year cumulative
incidence and event rate for lower gastrointestinal
hemorrhage was seen in 2002–2005 (9.08%, 31.97 per
1000 patient-years). In the same era, the 3-year cumulative
Table 1 Baseline characteristics of patients initiating chronic dialysis in Ontario, Canada from 1998 to 2008
Era, year of dialysis initiation Patient age, years
Characteristics Total 1998-2001 2002-2005 2006-2008 p-value 65-74 75-84 ≥85 p-value
n = 11,173 n = 3,837 n = 4,231 n = 3,105
Age, mean ± SD 75.8 ± 6.2 74.8 ± 5.8 76.1 ± 6.2 76.5 ± 6.43 <0.001
Women,% 42.3 42.3 42.0 42.6 0.873 41.6 42.5 44.2 0.286
Race,%
Caucasian 77.0 70.0 80.7 80.7 <0.001 73.9 79.4 80.5 <0.001
East Asian 6.2 6.6 6.1 5.8 5.9 6.2 7.6
South Asian 3.0 2.6 3.1 3.5 4.1 2.4 0.7
Aboriginal 1.1 1.1 1.0 1.2 1.7 0.6 0.4
Other 4.9 4.4 5.1 5.1 6.2 3.8 3.5
Unknown 7.9 15.5 4.0 3.6 8.1 7.7 7.4
Modality,%
Hemodialysis 81.4 78.5 82.3 80.4 <0.001 77.6 82.8 83.4 <0.001
Peritoneal dialysis 19.5 21.5 17.7 19.6 22.4 17.2 16.6
Medication*,%
Clopidogrel 4.5 0.5 5.6 8.0 <0.001 4.3 4.7 4.8 0.571
Warfarin 12.2 11.8 11.9 13.3 0.098 10.6 13.5 13.9 <0.001
Co-morbidity,%
Atrial fibrillation 14.7 14.0 15.3 14.9 0.258 12.2 16.6 17.8 <0.001
Stroke 5.0 5.8 5.0 4.0 0.003 5.2 4.9 4.5 0.514
Prior Major hemorrhage 10.1 8.9 10.1 11.7 <0.001 10.0 9.8 12.4 0.039
Acute coronary syndrome 13.6 12.7 14.7 13.2 0.026 1.8 2.1 1.8 0.588
Deep vein thrombosis & pulmonary embolism 1.9 1.8 1.8 2.3 0.202 1.8 2.1 1.8 0.588
Mechanical heart valve 1.3 0.9 1.4 1.5 0.022 1.5 1.2 0.3 0.009
Modified Charlson Co-morbidity Indexǂ,%
2 27.4 27.7 26.7 28.0 <0.001 26.8 27.5 30.2 <0.001
3 13.9 17.5 12.9 10.9 12.2 14.7 18.2
4 19.0 20.1 17.3 19.9 18.6 19.0 20.9
≥5 39.7 34.7 43.0 41.2 42.4 38.8 30.6
*Medication was based on evidence of medication prescription at dialysis initiation.
ǂ We used a modified Charlson Index that gave each individual on dialysis an automatic two-points for moderate-to-severe kidney disease.
Table 2 3-year cumulative incidence and incidence rates per 1,000 person year of total hemorrhages and hemorrhage
subtypes










N = 11, 173 1612 992 677 95 11 1660
3-year cumulative
incidence (%)
14.43 8.88 6.06 0.85 0.10 14.86
Event rate (per 1000
patient-years)
52.64 31.21 20.94 2.85 0.33 54.45
1Counted as the first major hemorrhage at any anatomical location.
2Counted as the first hemorrhage at this anatomical location.
3Gastrointestinal endoscopy included gastroscopy, colonoscopy, sigmoidoscopy, duodenoscopy & esophagoscopy, when the procedure occurred during
hospital stay.
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Figure 1 3-year cumulative incidence rate of all hemorrhage, its subtypes and related-endoscopy, stratified by age groups. A p-value of
0.005 was found in the gastrointestinal endoscopy group across age using Cochrane-Armitage test for trend.
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rhage was lowest (5.91%, 20.41 per 1000 patient-years). The
3-year cumulative incidence of gastrointestinal endoscopic
procedures ranged from 15.66 to 14.94% and was steady
over time (p = 0.34). Intra-cerebral hemorrhages increased
from 0.70 to 0.97%, p = 0.23 whereas the 3 year cumulative
incidence of subarachnoid hemorrhage was relatively low.
Dialysis modality and three-year cumulative incidence
and event rate of hemorrhage
The three-year cumulative incidence and event rate for
total hemorrhage and its subtypes were all lower amongTable 3 Secular trends of the 3-year cumulative incidence (%
its subtypes, related endoscopy and all-cause mortality
Outcome Total
Total hemorrhage 3-yr incidence 14.43
Event rate 52.64
Upper gastrointestinal 3-yr incidence 6.06
Event rate 20.94
Lower gastrointestinal 3-yr incidence 8.88
Event rate 31.21
Intra-cerebral 3-yr incidence 0.85
Event rate 2.85
Subarachnoid 3-yr incidence 0.10
Event rate 0.33
Gastrointestinal endoscopy 3-yr incidence 14.86
Event rate 54.45peritoneal dialysis patients compared to hemodialysis
however the differences were not statistically significant
(see Table 4). Patients on peritoneal dialysis did undergo
more gastrointestinal endoscopic procedures than patients
on hemodialysis (17.84 vs. 14.13%, p < 0.0001).
3-year cumulative incidence and secular trends of
hemorrhage and preceding prescription for anti-
thrombotic medications
Among the 1,612 patients with hemorrhages, 4.20 and
8.37 were prescribed clopidogrel in the preceding 30 and
120 days (Table 5). Warfarin prescriptions occurred in) and event rates of hemorrhage (per 1000 person years),
1998-2001 2002-2005 2006-2008 P value
14.15 14.72 14.36 0.78
51.57 53.87 52.29
6.12 5.91 6.18 0.95
21.19 20.41 21.33
8.84 9.08 8.66 0.83
31.01 31.97 30.42
0.70 0.90 0.97 0.23
2.35 3.01 3.24
0.05 0.14 0.10 0.51
0.17 0.47 0.32
15.66 14.06 14.94 0.34
57.76 51.36 54.61
Table 4 Total 3-year cumulative incidence and event rates of hemorrhage (per 1,000 person years), its subtypes, and
related endoscopy stratified by dialysis modality
Outcome Total P value
Hemodialysis Peritoneal dialysis
Total hemorrhage 3-yr incidence 14.63% 13.58% 0.21
Event rate 53.37 48.86
Upper gastrointestinal 3-yr incidence 6.09% 5.92% 0.76
Event rate 21.07 20.38
Lower gastrointestinal 3-yr incidence 9.04% 8.21% 0.22
Event rate 31.85 28.59
Intra-cerebral 3-yr incidence 0.88% 0.73% 0.51
Event rate 2.94 2.45
Subarachnoid 3-yr incidence - -
Event rate 0.30 0.46
Gastrointestinal endoscopy 3-yr incidence 14.13% 17.84% <0.0001
Event rate 51.64 66.24
Note: 3-year cumulative incidence of subarachnoid hemorrhage cell values were suppressed for the purposes of privacy and confidentiality.
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over half the hemorrhagic events observed occurred
within 30 days of prescription of either drug. Clopidrogrel
prescription prior to major bleeding increased over time
from 1998–2001 to 2006–2008 (p < 0.001) and during
the same time period, warfarin prescription declined
120 days prior to the event (p = 0.023). Co-prescription
of both warfarin and clopidogrel in the period prior to
a hemorrhage was relatively rare with a non-significant
increase over time from 0.7% to 3.4% (p = 0.07).Discussion
In this population-level study of older incident dialysis
patients in Ontario, Canada, the 3-year cumulative inci-
dence of hospitalization with hemorrhage was 14.43% or
one in seven patients. The most common site of bleeding
was lower gastrointestinal followed by upper gastrointes-
tinal, intra-cerebral and subarachnoid hemorrhage, and
many patients received an endoscopic procedure during
their hospital admission. The incidence of hemorrhage
was stable across age groups, over time, by dialysis modal-
ity and elevated among those recently prescribed anti-
thrombotic medications. Among incident dialysis patients,Table 5 Secular trends of the proportion of patients who rece
120 days preceding a hemorrhagic event
Medication Total 1998-20
Clopidogrel (30 days) 4.2% 1.7%
Clopidogrel (120 days) 8.4% 2.6%
Warfarin (30 days) 16.6% 17.5%
Warfarin (120 days) 29.5% 33.3%
Warfarin + Clopidogrel (120 days) 1.8% 0.7%the burden of hemorrhage is high and population-specific
interventions are warranted.
Our finding of a high incidence of hemorrhage among
incident dialysis patients with an observed rate of 52.64
per 1,000 person years is consistent with previous studies
[2,3,24]. In prior large dialysis cohort studies event rates
have ranged from 35.4 to 80 per 1,000 person-years [2,3].
Differences in the reported rates are attributable to
variations in the definition of hemorrhage and inclusion
criteria of individual studies. Olsen et al. examined
hemorrhage requiring hospitalization in patients with
atrial fibrillation and included urinary tract and airway
hemorrhage [3]. Sood et al. reported an event rate of
80/1000 patient-years for hemorrhage with hospitalization
with a broader definition including epistaxis, vascular
access-related hemorrhage and subdural hematoma, and
the study cohort included both incident and prevalent dia-
lysis patients [2]. Of note the Canadian dialysis population
may differ from international counterparts with relatively
higher use of central venous catheters and warfarin all of
which may impact the risk of hemorrhage [2,11].
As our rate estimates were determined in incident dia-
lysis patients, they could serve to inform patients of their
risk prior to dialysis initiation. The ability to quantitateived an anti-thrombotic medication prescription 30 and
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initiation is increasingly important with the shift in
demographics of the dialysis population to the elderly
and need to balance quantity and quality of life. We
further calculated the three-year cumulative incidence
of hemorrhage as it may be a simple and meaningful
way to communicate risk and understand disease bur-
den from a patient perspective [25]. We found a 3-year
cumulative incidence of 14.43% thus roughly 1 in 7 elderly
dialysis patients will experience a hemorrhage requiring
hospitalization within 3 years of dialysis initiation. This
could be used in pre-dialysis discussions with patients
to help them understand the risks of complications
after dialysis initiation.
Among the specific subtypes of hemorrhagic events,
we found upper and lower gastrointestinal hemorrhage
(both well validated definitions of hemorrhage) to be the
most common and roughly twenty to one hundred-fold
higher in the elderly dialysis population compared to the
general population [6,26,27]. Upper gastrointestinal
hemorrhage has been previously reported in large US
ESRD cohorts ranging from 23–57 per 1,000 person-
years [10,28]. This is comparable to our rate of 20.94 per
1000 patient-years. Similarly, subarachnoid hemorrhage
and intra-cerebral hemorrhage were found to occur at
rates 3- to 10- fold higher in the dialysis population
compared to those reported in the general population
[29]. The rate of subarachnoid hemorrhage among
those with ESRD was recently reported as 3-fold higher
in the US compared to our study (0.74 vs. 0.33 per
1000-patient years) [29]. Differences among the rates
may be attributable to a higher prevalence of associated
risk factors (such as women US: 56.3% vs Canada: 42.3%
and African Americans US: 25.7% vs Canada <5%) [29].
The risk of hemorrhage was stable over time, by age
group and dialysis modality. The steady temporal trends
have been reported in the US dialysis populations for
upper gastrointestinal and subarachnoid hemorrhage,
however, the comparable risk across age groups to our
knowledge has not been previously reported [10,29]. The
stable temporal trends in the dialysis population are in
contrast to the general population where GI and SAH
have been reported to be declining steadily over the last
two decades [6,30]. This has been attributed to advances
in prevention (acid suppressing medications) or related
risk factors (hypertension treatment for subarachnoid
hemorrhage) in the general population. Yet it remains
unclear whether therapies are effective or treatment targets
are similar or comparable in the dialysis population. The
stable risk of hemorrhage with advancing age is reassuring
and again provides important prognostic information for
the elderly initiating dialysis. Of note, the absence of an
increase in hemorrhagic events in the elderly may reflect a
selection bias as elderly patients who are less likely toexperience a hemorrhagic event may also be more apt
to choose dialysis therapy over conservative treatments.
Surprisingly despite similar hemorrhage rates, individ-
uals ≥ 85 were much less likely to receive related endo-
scopic procedures (p = 0.005). Although the specific
reasons for not performing endoscopic procedures were
unknown, there is an increased risk of complications,
often due to the bowel preparation or anesthetics, with
advancing age and frailty [31]. The hemorrhagic risk
appears to be similar based on dialysis modalities with
the only difference detected being in gastrointestinal
endoscopic procedures. It should be noted that the two
cohorts are known to differ significantly in terms of demo-
graphics, co-morbidities, functionality and exposures [32].
These disparities were not accounted for in the present
analysis and represent future areas on investigation.
A question of interest is the risk of hemorrhage with the
use of anti-thrombotic medications [1,33-35]. We observed
a large number of hemorrhagic events occurring following
a recent warfarin or clopidogrel prescription. Of concern,
the incidence of hemorrhage associated with clopidogrel
prescription use was trending upward during the study
period. To date, there remains very little evidence for
efficacy of these medications in dialysis patients aside
from warfarin use for a recent or recurrent thrombus
[36,37]. Despite the increase in prescriptions for clopi-
dogrel associated with hemorrhagic events over time,
there was no significant increase in total hemorrhagic
events. Whether this represents possible selection bias,
increased use of co-interventions or declines in hemor-
rhagic events among patients not treated with anti-
thrombotics remains unknown.
Our study has a number of strengths. Our definition of
hemorrhage was stringent and limited to severe events
requiring hospitalization. Previous studies included surro-
gate measures of bleeding (such as blood transfusion),
bleeding events managed in the outpatient setting and
subtypes with limited clinical impact (epistaxis) [2,3,24].
We used well validated definitions for our outcomes
and excluded those lacking validation (vascular access
related bleeding). We determined a three-year follow-up
to ensure estimates of hemorrhage incidence would be
useful for sample size calculations in future clinical trials.
As CORR captures nearly all incident dialysis patients in
Canada, our findings are representative and generalizable.
Our study has some limitations. We did not include
traumatic or peri-operative bleeding events. Medication
prescription was obtained only in cross section at the
initiation of dialysis or 120 days preceding an event, and
did not account for medication continuation and discon-
tinuation over time. We lacked information on ASA use
or INR control among warfarin users. We did not ac-
count for recurrent events or events in prevalent dialysis
patients which would have considerably increased our
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heparin-use during the hemodialysis procedure nor did
we account for changes in modality over time.
Conclusion
Among incident dialysis patients are at high risk of
hemorrhagic events requiring hospitalization. These events
are stable over time, across age groups and by dialysis
modality. Further studies of risk stratification for these
events, and strategies to reduce these events, are needed.
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